This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kawa, K. Articles by Tsuchida, Y. Search for Related Content PubMed PubMed Citation Articles by Kawa, K. Articles by Tsuchida, Y. Social Bookmarking                            What's this?

Long-Term Survivors of Advanced Neuroblastoma With MYCN Amplification: A Report of 19 Patients Surviving Disease-Free for More Than 66 Months

From The Study Group of Japan for Treatment of Advanced Neuroblastoma, Izumi, Chiba, Tsukuba, and Gunma, Japan.

Address reprint requests to Yoshiaki Tsuchida, MD, Gunma Children's Medical Center, 779 Shimohakoda, Hokkitsu, Seta-gun, Gunma 377-8577, Japan; email tuchida{at}gcmc.pref.gunma.jp

PURPOSE: According to initial reports, stage 4 neuroblastoma patients with amplification of the MYCN proto-oncogene developed progressive disease within 8 months. The prognosis for such patients, however, should now be reevaluated in light of recent results achieved with up-to-date combination chemotherapy.

PATIENTS AND METHODS: Patients with stage 3, 4, and 4S neuroblastoma and more than 10 copies of MYCN received induction chemotherapy, which from January 1985 to February 1991 consisted of regimen A₁ (cyclophosphamide 1,200 mg/m² on day 1, vincristine 1.5 mg/m² on day 1, pirarubicin 40 mg/m² on day 3, and cisplatin 90 mg/m² on day 5) and from March 1991 to September 1993 consisted of regimen A₃ (cyclophosphamide 1,200 mg/m² on days 1 and 2, pirarubicin 40 mg/m² on day 3, etoposide 100 mg/m² on days 1 through 5, and continuous infusion cisplatin 25 mg/m² on days 1 through 5). Most of these patients underwent radical surgery to remove the original tumor and local metastases, irradiation, and supralethal preconditioning regimens, followed by blood stem-cell transplantation (SCT). Data on the patients were collected in December 1998, and the factors contributing to disease-free survival were analyzed.

RESULTS: During the study period, 66 patients with more than 10 copies of MYCN were treated. Five of nine patients with stage 3 disease, 13 of 55 with stage 4, and one of two with stage 4S survived for at least 66 months. It is interesting that all but one patient who survived for more than 66 months underwent SCT, in contrast with only five of 45 patients who died.

CONCLUSION: Not all patients with advanced neuroblastoma who have more than 10 copies of MYCN will die. The requisites for survival in such patients seem to be intensive induction chemotherapy, effective surgery, irradiation, and the use of SCT.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Canete, M. Gerrard, H. Rubie, V. Castel, A. Di Cataldo, C. Munzer, R. Ladenstein, B. Brichard, J. D. Bermudez, J. Couturier, et al. Poor Survival for Infants With MYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience J. Clin. Oncol., March 1, 2009; 27(7): 1014 - 1019. [Abstract] [Full Text] [PDF]

				A. Weber, P. Imisch, E. Bergmann, and H. Christiansen Coamplification of DDX1 Correlates With an Improved Survival Probability in Children With MYCN-Amplified Human Neuroblastoma J. Clin. Oncol., July 1, 2004; 22(13): 2681 - 2690. [Abstract] [Full Text] [PDF]

				F. H. Schilling, C. Spix, F. Berthold, R. Erttmann, N. Fehse, B. Hero, G. Klein, J. Sander, K. Schwarz, J. Treuner, et al. Neuroblastoma Screening at One Year of Age N. Engl. J. Med., April 4, 2002; 346(14): 1047 - 1053. [Abstract] [Full Text] [PDF]

				S. A. Burchill, I. J. Lewis, K. R. Abrams, R. Riley, J. Imeson, A. D.J. Pearson, R. Pinkerton, and P. Selby Circulating Neuroblastoma Cells Detected by Reverse Transcriptase Polymerase Chain Reaction for Tyrosine Hydroxylase mRNA Are an Independent Poor Prognostic Indicator in Stage 4 Neuroblastoma in Children Over 1 Year J. Clin. Oncol., March 15, 2001; 19(6): 1795 - 1801. [Abstract] [Full Text] [PDF]